Chapter

Systemic treatment of recurrence after local therapies

Daniel M Moreira, Stephen J Freedland, Judd W Moul and Lionel L Bañez

in Systemic Treatment of Prostate Cancer

Published on behalf of Oxford University Press

ISBN: 9780199561421
Published online May 2011 | e-ISBN: 9780199607372 | DOI: http://dx.doi.org/10.1093/med/9780199561421.003.0004

Series: Oxford Oncology Library

Systemic treatment of recurrence after local therapies

Show Summary Details

Preview

• Biochemical recurrence (BCR) is defined as prostate-specific antigen (PSA) rise above 0.2ng/mL after radical prostatectomy and PSA value greater than nadir plus 2ng/mL after other local therapies • Patients with local recurrence after local therapies may benefit from local salvage therapies (e.g. salvage prostatectomy or salvage radiotherapy) • Surgical castration and luteinizing hormone-releasing hormone (LHRH) agonists are currently first-line systemic therapy for prostate cancer recurrence after local therapies • Hormonal therapy is associated with sexual dysfunction, cognitive impairment, osteoporosis, lipid abnormalities, loss of muscle mass, anemia, diabetes, and cardiovascular disease • Androgen deprivation therapy (ADT) for PSA-only relapse should be reserved for patients with high risk of progression wherein benefits of ADT outweighs risks for its side-effects.

Chapter.  3094 words. 

Subjects: Clinical Oncology

Full text: subscription required

How to subscribe Recommend to my Librarian

Buy this work at Oxford University Press »

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.